The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Ontario's addictions minister says the best way to curb the entry of people to the opioid epidemic is to treat youth mental ...

NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...

A new painkiller was approved by the Food and Drug Administration (FDA) on Thursday, and is one step closer to making its way ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...